Oevbiu4psssizskmuh2e admera

Admera Health LLC

South Plainfield, New Jersey, US

News Update:
We are currently having a promotion for miRNAse! Please inquire for more information.

Admera Health is an advanced molecular diagnostics and research service provider. Utilizing genomic and proteomic technology platforms (such as next generation sequencing and aptamer), together with advanced bioinformatics, Custom Services of Admera Health seeks to redefine the delivery of transformative, valuable solutions for all researchers and biopharma companies.

Custom Services of Admera Health operates in a CLIA-certified and CAP-accredited laboratory for the development, validation, and delivery of laboratory developed tests (LDTs) as well as RUO (Research Use Only) services. We are committed to maintaining compliance with all clinical regulations and to upholding the highest quality standards for all our projects. Admera Health is the winner of 2016 Frost & Sullivan BEST PRACTICE AWARD.

Please... Show more »

News Update:
We are currently having a promotion for miRNAse! Please inquire for more information.

Admera Health is an advanced molecular diagnostics and research service provider. Utilizing genomic and proteomic technology platforms (such as next generation sequencing and aptamer), together with advanced bioinformatics, Custom Services of Admera Health seeks to redefine the delivery of transformative, valuable solutions for all researchers and biopharma companies.

Custom Services of Admera Health operates in a CLIA-certified and CAP-accredited laboratory for the development, validation, and delivery of laboratory developed tests (LDTs) as well as RUO (Research Use Only) services. We are committed to maintaining compliance with all clinical regulations and to upholding the highest quality standards for all our projects. Admera Health is the winner of 2016 Frost & Sullivan BEST PRACTICE AWARD.

Please follow the link for more information:
https://d2vb59yh1h6wmu.cloudfront.net/wp-content/uploads/2018/01/Admera-Health-RUO-Services-2018.pdf

« Show less

Admera Health LLC has not listed any services.

Targeted Cancer Gene Panel
Price on request

Illumina TruSight Cancer - targets 94 genes
Illumina TruSight Tumor 170 - covers 170 genes for both RNA and DNA samples.
QIAseq Targeted DNA Panels - Human Colorectal Cancer Panel

TruSight Tumor 170
TruSight Tumor 170 covers 170 genes for both RNA and DNA samples.
Starting material 40ng nucleic acid (if lower, please... Show more »

Illumina TruSight Cancer - targets 94 genes
Illumina TruSight Tumor 170 - covers 170 genes for both RNA and DNA samples.
QIAseq Targeted DNA Panels - Human Colorectal Cancer Panel

TruSight Tumor 170
TruSight Tumor 170 covers 170 genes for both RNA and DNA samples.
Starting material 40ng nucleic acid (if lower, please inquire for more details)
Extraction Service Available
Can accomodate on Illumina systems
TAT: 28-35 days
Starting coverage per sample at 100x and go up to 500x coverage (more coverage, please inquire for more details)
Deliverables: raw sequencing data

Illumina TruSight Cancer
Price on request
TruSight Cancer targets 94 genes
Starting material at 50ng gDNA (or lower, please inquire)
Extraction Service Available
Can accomodate on any Illumina Platform
TAT: 28-35 days
Starting coverage per sample at 100x and go up to 1,000x coverage
Deliverables: raw sequencing data, technical report (please inquire)

QIAseq Targeted DNA Panels - Human Colorectal Cancer Panel
Starting material at 10ng gDNA (or lower, please inquire)
Extraction Service Available
Can accomodate on any Illumina Platform
TAT: 28-35 days
Starting coverage per sample at 500x and go up to 10,000x coverage
Deliverables: raw sequencing data, technical report (please inquire)

https://www.qiagen.com/us/shop/sample-technologies/dna/genomic-dna/qiaseq-targeted-dna-panels/?catno=DHS-002Z#geneglobe

« Show less
MicroRNA (miRNA) Sequencing
Starting at $150.00 per sample

MicroRNA (miRNA) Sequencing
miRNA Sequencing is also a type of RNA-Seq with the only difference being that the input is enriched for small RNAs. miRNA enables researchers to study tissue-specific expression patterns, isoforms of miRNAs, disease relationships and to find out novel uncharacterized miRNAs.

With unprecedented... Show more »

MicroRNA (miRNA) Sequencing
miRNA Sequencing is also a type of RNA-Seq with the only difference being that the input is enriched for small RNAs. miRNA enables researchers to study tissue-specific expression patterns, isoforms of miRNAs, disease relationships and to find out novel uncharacterized miRNAs.

With unprecedented sensitivity and dynamic range, small RNA sequencing methods allow for the most accurate detection and quantification of rare small RNA sequences.

SMARTer smRNA-Seq Kit for Illumina
NEBNext Small RNA Library Prep Set for Illumina
TruSeq Small RNA Library Preparation Kits

« Show less
Illumina HiSeq Sequencing
Price on request

Hiseq 2500
Hiseq 4000
Hiseq X
Novaseq
Estimated TAT; 2 weeks

Hiseq 2500
Hiseq 4000
Hiseq X
Novaseq
Estimated TAT; 2 weeks

« Show less
Illumina NextSeq Sequencing
Price on request

Nextseq Sequencing Only
Estimated Output: 130-400M total reads
Estimated Output : 3-5days

NextSeq 500/550 High Output v2 kit (75 cycles) $1600

NextSeq 500/550 Mid Output v2 kit (150 cycles) $1200

NextSeq 500/550 Mid Output v2 kit (300 cycles) $1900

NextSeq 500/550 High Output v2 kit (300 cycles) $5000

Nextseq Sequencing Only
Estimated Output: 130-400M total reads
Estimated Output : 3-5days

NextSeq 500/550 High Output v2 kit (75 cycles) $1600

NextSeq 500/550 Mid Output v2 kit (150 cycles) $1200

NextSeq 500/550 Mid Output v2 kit (300 cycles) $1900

NextSeq 500/550 High Output v2 kit (300 cycles) $5000

« Show less
Illumina MiSeq Sequencing
Starting at $900.00 per run

MiSeq 2x150 V2 Sequencing Only
Estimated Output: 24-30M total reads (12-15M reads each direction)
Estimated TAT: 3-5 days

MiSeq 2x150 V2 Sequencing Only
Estimated Output: 24-30M total reads (12-15M reads each direction)
Estimated TAT: 3-5 days

« Show less
16S rRNA
Illumina MiSeq
Amplicon library
cDNA library
Illumina
NGS
mRNA
miRNA
RNA-Seq Library Preparation
Starting at $200.00 per sample

• Service description:
Transcriptome profiling with RNA-Seq is a powerful tool for analyzing gene expression levels within an individual sample, as well as for comparing differential gene expression between multiple samples. Additionally, RNA-Seq is capable of detectingthe presence of novel isoforms, alternatively spliced... Show more »

• Service description:
Transcriptome profiling with RNA-Seq is a powerful tool for analyzing gene expression levels within an individual sample, as well as for comparing differential gene expression between multiple samples. Additionally, RNA-Seq is capable of detectingthe presence of novel isoforms, alternatively spliced transcripts; Potential gene fusion events can also be detected through analysis of RNA-seq data.

• Advantages:
a) Complete solution from RNA extraction to BI analysis
b) Variable sample type: mRNA, Whole transcriptome, Targeted, miRNA, Low Input, Ribosomal profiling
c) Ability to detect transcripts with low expression levels
d) Custom targeted RNA-Seq service available. Please inquire with a list of targets of interest
e) Low cost and fast TAT

• Service grade: Research Use Only (RUO) in a CLIA environment

• Deliverables:
a) Raw data as FASTQ files
b) Quality control result
c) Gene expression analysis (FPKM in both gene and transcript levels)
d) Alternative splicing/novel isoform analysis
e) List of potential gene fusion events if detected.

• TAT: 2 weeks

• Sample requirements (extra QC may needed)
a) Extracted RNA
b) Fresh frozen tissue or cell pellet
c) FFPE tissue on slides

• Sequencing platforms and price upon to request:High depth of coverage and long reads available, please inquire for details.

• Library preparation options and price*
a) NEBNext® Ultra™ RNA Library Prep Kit for Illumina
b) NEBNext® Ultra™ Directional RNA Library Prep Kit
c) TruSeq Small RNA Library Preparation Kits
d) ArcherDx Fusionplex
e) SMART-Seq v4 Ultra Low Input RNA Kit
f) TruSeq RNA Access Kit
Special library prep method upon to request

• Basic data analysisis included during promotional period as follows:Read mapping (Tophat) and Gene expression quantification (Cufflinks /FPKM) for human,Single Nucleotide Variation discovery, Fusion Gene Detection *
Additional charge may apply for special requirement

• Data security: biometrically restricted laboratory access and closed loop data behind firewall and data room also biometrically restricted. 1 year FREE storage of raw data

Promotion period: Febuary 1, 2018 to May 24, 2018

« Show less
RNA Sequencing
Starting at $200.00 per library

• Service description:
Transcriptome profiling with RNA-Seq is a powerful tool for analyzing gene expression levels within an individual sample, as well as for comparing differential gene expression between multiple samples. Additionally, RNA-Seq is capable of detectingthe presence of novel isoforms, alternatively spliced... Show more »

• Service description:
Transcriptome profiling with RNA-Seq is a powerful tool for analyzing gene expression levels within an individual sample, as well as for comparing differential gene expression between multiple samples. Additionally, RNA-Seq is capable of detectingthe presence of novel isoforms, alternatively spliced transcripts; Potential gene fusion events can also be detected through analysis of RNA-seq data.

• Advantages:
a) Complete solution from RNA extraction to BI analysis
b) Variable sample type: mRNA, Whole transcriptome, Targeted, miRNA, Low Input, Ribosomal profiling
c) Ability to detect transcripts with low expression levels
d) Custom targeted RNA-Seq service available. Please inquire with a list of targets of interest
e) Low cost and fast TAT

• Service grade: Research Use Only (RUO) in a CLIA environment

• Deliverables:
a) Raw data as FASTQ files
b) Quality control result
c) Gene expression analysis (FPKM in both gene and transcript levels)
d) Alternative splicing/novel isoform analysis
e) List of potential gene fusion events if detected.

• TAT: 2 weeks

• Sample requirements (extra QC may needed)
a) Extracted RNA
b) Fresh frozen tissue or cell pellet
c) FFPE tissue on slides

• Sequencing platforms and price upon to request:High depth of coverage and long reads available, please inquire for details.

• Library preparation options and price*
a) NEBNext® Ultra™ RNA Library Prep Kit for Illumina
b) NEBNext® Ultra™ Directional RNA Library Prep Kit
c) TruSeq Small RNA Library Preparation Kits
d) ArcherDx Fusionplex
e) SMART-Seq v4 Ultra Low Input RNA Kit
f) TruSeq RNA Access Kit
Special library prep method upon to request

• Basic data analysisis included during promotional period as follows:Read mapping (Tophat) and Gene expression quantification (Cufflinks /FPKM) for human,Single Nucleotide Variation discovery, Fusion Gene Detection *
Additional charge may apply for special requirement

• Data security: biometrically restricted laboratory access and closed loop data behind firewall and data room also biometrically restricted. 1 year FREE storage of raw data

Promotion period: Febuary 1, 2016 to May 24, 2016

« Show less
Illumina HiSeq 2500 sequencing system
Next Seq 500
Human
Illumina Stranded mRNA Library Prep Kit
Illumina TruSeq Small RNA Library Prep Kit
Illumina TruSeq Stranded mRNA Library Prep Kit
Tophat
Cufflinks
Archerdx
Illumina MiSeq
Whole Genome Sequencing
Starting at $1,500.00 per sample

Human whole genome sequencing allows for detection of variations to discover potential correlations to certain disease risks, and it can also play a role as molecular biomarkers for disease diagnosis and prediction.
De novo sequencing is typically performed without prior knowledge of the sequencing data, De novo sequencing has... Show more »

Human whole genome sequencing allows for detection of variations to discover potential correlations to certain disease risks, and it can also play a role as molecular biomarkers for disease diagnosis and prediction.
De novo sequencing is typically performed without prior knowledge of the sequencing data, De novo sequencing has proven successful for confirming and expanding upon results from database searches, providing excellent resources for understanding a species.Some of the most crucial information, obtained by resequencing of organism’s genome DNA, are the individual variations in the genome, such as single nucleotide polymorphism(SNP), copy number variation(CNV), and structural variation

• Advantages:
a) Low cost
b) High coverage depth and uniformity
c) Short TAT

• Service grade: Research Use Only (RUO) in a CLIA environment

• Genes/regions covered: Human whole genome

• Deliverables:
FASTQ, BAM and VCF files

• Sequencing depth:
Mean depth of coverage: ≥ 30x
Higher depth of coverage available for additional charges, please inquire for details.

• TAT: 3 weeks

• Sample requirements:
Types of samples accepted:
a) Saliva (please request sample collection supplies)
b) 5 ml Blood in a EDTA-coated tube
c) High quality genomic human DNA: a minimum of 100 nanogram as quantified by Qubit 2.0
d) Bisulfite sequencing (WGBS) per request

Purity of genomic human DNA samples:
a) OD260/280 ratio is between 1.8 to 2.0
b) OD260/230 ratio is between 1.5 to 2.0

• Sequencing platforms:
Illumina HiSeq X Ten Platform, Paired-end150 bp

• Library preparation options:
KAPA Hyper Prep Kits
TruSeq DNA Methylation Kit

• Data security: biometrically restricted laboratory access and closed loop data behind firewall and data room also biometrically restricted

• Promotion period: April 1, 2016 toMay 24, 2016, minimum sample amount: 3

« Show less
Whole Exome Sequencing (WES)
Starting at $549.00 per sample

• Service description:
Whole Exome Sequencing (WES) is aimed to sequence all the protein-coding regions or exons in a genome, collectively known as exome. There are approximately 180,000 exons which represent less than 2% of the human genome. As most of the disease-related variants are located in the exons, WES is thought to be... Show more »

• Service description:
Whole Exome Sequencing (WES) is aimed to sequence all the protein-coding regions or exons in a genome, collectively known as exome. There are approximately 180,000 exons which represent less than 2% of the human genome. As most of the disease-related variants are located in the exons, WES is thought to be an efficient way to understand the genetic cause of diseases or conditions. We provide a very cost-effective, high quality WES service.

• Advantages:
a) Low cost
b) High coverage depth and uniformity
c) Short TAT

• Service grade: Research Use Only (RUO) in a CLIA environment

• Genes/regions covered: Human exons in approximately 22,000 genes.

• Deliverables:
a) FASTQ, BAM and VCF files
b) Variant annotation

• Sequencing depth:
a) Mean depth of coverage: ≥ 100x
b) 90% of exons covered at ≥ 20x depth
c) Uniformity of Coverage (Pct > 0.2*mean) >90%
Higher depth of coverage available for additional charges, please inquire for details.

• TAT: 3 weeks

• Sample requirements:
Types of samples accepted:
a) Saliva (please request sample collection supplies)
b) 5 ml Blood in a EDTA-coated tube
c) High quality genomic human DNA: a minimum of 500 nanogram as quantified by Qubit 2.0

Purity of genomic human DNA samples:
a) OD260/280 ratio is between 1.8 to 2.0
b) OD260/230 ratio is between 1.5 to 2.0

• Sequencing platforms:
a) Illumina NextSeq paired-end 2x150 bp reads
b) Illumina HiSeq paired-end 2x150 bp reads

• Library preparation options:
a) xGen® Exome Research Panel v1.0*
b) TruSeq Exome Library Prep kit*
c) SureSelect Human All Exon V6
d) Nextera® Rapid Capture Expanded Exome Kit (additional charges apply, please inquire for details)
e) SureSelect Focused Exome
f ) SureSelect Human All Exon V5
g) SureSelect Mouse All Exon (Please inquire for more details)

• Data security: biometrically restricted laboratory access, closed loop data behind firewall, and biometrically restricted data room

« Show less
Illumina HiSeq 2500 sequencing system
Illumina NextSeq 500 sequencing system
Human
Agilent SureSelect XT Human All Exon v5
Illumina HiSeq X Ten
Agilent SureSelect Focused Exome
Mouse
Agilent OneSeq
Illumina HiSeq 4000
Agilent SureSelect XT Human All Exon v4
xGen Lockdown Panels
Agilent SureSelect
Metagenomics
Starting at $200.00 per sample

Metagenomics is the study of genetic material recovered directly from environmental samples. The broad field may also be referred to as environmental genomics, ecogenomics or community genomics. While traditional microbiology and microbial genome sequencing and genomics rely upon cultivated clonal cultures, early environmental... Show more »

Metagenomics is the study of genetic material recovered directly from environmental samples. The broad field may also be referred to as environmental genomics, ecogenomics or community genomics. While traditional microbiology and microbial genome sequencing and genomics rely upon cultivated clonal cultures, early environmental gene sequencing cloned specific genes (often the 16S rRNA gene) to produce a profile of diversity in a natural sample. Such work revealed that the vast majority of microbial biodiversity had been missed by cultivation-based methods. Recent studies use either "shotgun" or PCR directed sequencing to get largely unbiased samples of all genes from all the members of the sampled communities. Because of its ability to reveal the previously hidden diversity of microscopic life, metagenomics offers a powerful lens for viewing the microbial world that has the potential to revolutionize understanding of the entire living world. As the price of DNA sequencing continues to fall, metagenomics now allows microbial ecology to be investigated at a much greater scale and detail than before.

Advantages:
• Higher sensitivity
• Low bias
• Cost-effective
• Fast turnaround

Region coverage:
Whole Genome Sequencing

Deliverables:
• Raw data as FASTQ files
•Assembly and denovo per request

TAT:
• 2 weeks

Sample Submission:
• Cell pellets
• High quality genomic DNA (a minimum of 100ng as quantified by Qubit 2.0)
• OD260/280 ratio is between 1.8 to 2.0
• OD260/230 ratio is between 1.5 to 2.0

Data security: biometrically restricted laboratory access,closed loop data behind firewall, and biometrically restricted data room

Promotion period:
Feburary 1, 2016 to May 24, 2016; minimum sample amount: 24

« Show less
Next Seq 500
Illumina HiSeq 4000
Illumina HiSeq 3000
Illumina MiSeq
qPCR
Quantitative PCR
Price on request

Quantitative Real Time PCR (qPCR)
Admera Health, a molecular diagnostics company, offers qualitative and quantitative real time PCR for all of your NGS based DNA and RNA needs. Run on our QuantStudio, we offer qPCR services using a variety of commercial kits on SYBR Green-based assays. Inquire for a quote today and speak to one... Show more »

Quantitative Real Time PCR (qPCR)
Admera Health, a molecular diagnostics company, offers qualitative and quantitative real time PCR for all of your NGS based DNA and RNA needs. Run on our QuantStudio, we offer qPCR services using a variety of commercial kits on SYBR Green-based assays. Inquire for a quote today and speak to one of our experienced Scientist about your project needs.

Service Description:
Real Time PCR allows for the enzymatic amplification and fluorescent labeling of a short, specific region or your template. As amplification continues, fluorescence is released in a manner that is directly proportional to the amount of DNA that is amplified. The release of fluorescence during amplification is monitored in real time providing highly sensitive quantitative data.
The results gained from performing RT-qPCR have a variety of applications, including identifying microorganisms, genotyping, detecting SNPs, primer efficiency, precise quantitation measures, etc.
Advantages:
Submitting your samples to Admera Health for qPCR will provide you with fast turnaround times and affordable pricing to stay within your time constraints and budget.
Deliverables:
•Upon completion of your project, you will receive the RAW data and an exported excel file.
TAT :
•1-2 weeks from arrival of samples at our facility.
Sample Acceptance Criteria:
DNA
•Concentration – starting from as little as 20ng per sample.

RNA
•Concentration – starting from as little as 100ng per sample.

Data security
• Biometrically restricted laboratory access, closed loop data behind firewall, and biometrically restricted data room

« Show less
HLA Typing
Starting at $698.00 per sample

Service description
Human leukocyte antigen (HLA) genes are the most polymorphic in the human genome. They play a pivotal role in the immune response and have been implicated in numerous human pathologies, especially autoimmunity and infectious diseases. When a mutation occurs in any of the 11 HLA loci, our body loses the ability... Show more »

Service description
Human leukocyte antigen (HLA) genes are the most polymorphic in the human genome. They play a pivotal role in the immune response and have been implicated in numerous human pathologies, especially autoimmunity and infectious diseases. When a mutation occurs in any of the 11 HLA loci, our body loses the ability to distinguish between self cells and non-self cells. Furthermore, mutations can cause transplant rejection, autoimmune responses, promotion of cancer, and drug sensitivity.

Advantages
HLA typing has been known to be difficult for many reasons including ambiguous allele variability. With Illumina’s TruSight™ HLA Sequencing Panel, we offer sample-to-report services. Unlike conventional methods, which require multiple assays, multiple systems, and multiple analysis programs, we are able to achieve high-throughput and high-resolution human leukocyte antigen (HLA) typing results.

• Definitive, unambiguous results
• High coverage depth and uniformity
• Short TAT

Genes/regions covered:
Loci Target Sequence
HLA-A 4.1 kb (entire gene)
HLA-B 2.6 kb (exons 1-7 + introns)
HLA-C 4.2 kb (entire gene)
HLA-DRB1/3/4/5 4.1 kb (exon 2, intron 4)
HLA-DQB1 7.1 kb (exon 1-3’UTR)
HLA-DPB1 9.7 kb (exon 2-3’UTR)
HLA-DQA1 7.3 kb (entire gene)
HLA-DPA1 10.3 kb (entire gene)

Deliverables
• FASTQ, BAM, and VCF files
• Variant annotation
• Technical report
Sequencing depth
• Mean depth of coverage: ≥ 300x
TAT
• 2 weeks

Sample acceptance criteria:
• Saliva (please request sample collection supplies)
• 5 ml Blood in a EDTA-coated tube
• High quality genomic human DNA (a minimum of 2.0 ug as quantified by Qubit 2.0)
Purity of genomic human DNA samples:
• OD260/280 ratio is between 1.8 to 2.0
• OD260/230 ratio is between 1.5 to 2.0
Sequencing platforms:
• Illumina MiSeq paired-end 2x250 bp reads
Library preparation
• Illumina’s TruSight™ HLA Sequencing Panel

Software & Reporting
• Conexio Genomics

Data security
• Biometrically restricted laboratory access, closed loop data behind firewall, and biometrically restricted data room

Promotion period
• February 1, 2016 to May 24, 2016; minimum sample amount: 8

« Show less
Illumina MiSeq sequencing system
Illumina NextSeq 500 sequencing system
Human
TruSight HLA Sequencing Panel
CAR-T Cell Therapy Development
Price on request

Regulatable CAR-T

Chimeric Antigen Receptor T-cell (CAR-T) therapy is one of the new immuno-therapies showing promising results. However, it has shortcomings such as off-targeting and toxicity in clinical trials. In order to overcome this, Admera Health has developed a regulatable CAR-T platform based on aptamer technology.... Show more »

Regulatable CAR-T

Chimeric Antigen Receptor T-cell (CAR-T) therapy is one of the new immuno-therapies showing promising results. However, it has shortcomings such as off-targeting and toxicity in clinical trials. In order to overcome this, Admera Health has developed a regulatable CAR-T platform based on aptamer technology. The expression of CAR can be controlled by certain small molecules so that the side effects of CAR-T therapy can be controlled and minimized.

« Show less
Microsatellite Instability Testing
Price on request

MSI-H/dMMR

A deficient mismatch repair (dMMR) system causes persistence of DNA mismatches in microsatellites. Tumors that have a dMMR system can develop MSI (microsatellite instability). Microsatellite instability high (MSI-H) phenotype can serve as a key indicator for ICI therapy efficacy. Admera Health offers MSI/dMMR and OncoGx DNA sequencing for MSI-H/dMMR analysis.

MSI-H/dMMR

A deficient mismatch repair (dMMR) system causes persistence of DNA mismatches in microsatellites. Tumors that have a dMMR system can develop MSI (microsatellite instability). Microsatellite instability high (MSI-H) phenotype can serve as a key indicator for ICI therapy efficacy. Admera Health offers MSI/dMMR and OncoGx DNA sequencing for MSI-H/dMMR analysis.

« Show less
Tumor Mutation Burden Analysis
Price on request

Tumor mutation burden is one of the indicators for Immune checkpoint inhibitor therapy efficacy. Patients with higher tumor mutation burden usually have better response to immuno-therapy such as PD-1 inhibitor. Admera Health offers WES and OncoGx DNA panel sequencing for tumor mutation burden analysis.

Tumor mutation burden is one of the indicators for Immune checkpoint inhibitor therapy efficacy. Patients with higher tumor mutation burden usually have better response to immuno-therapy such as PD-1 inhibitor. Admera Health offers WES and OncoGx DNA panel sequencing for tumor mutation burden analysis.

« Show less
Immune Repertoire Sequencing
Price on request

There are 6 key types of immune proteins including 4 types of T-cell receptors and 2 types of immunoglobulins. High diversity of immune repertoire can be used as a prediction indicator for immune therapy. We can analyze the immune repertoire by TCR/BCR (T- and B-cell Receptor) sequencing.

There are 6 key types of immune proteins including 4 types of T-cell receptors and 2 types of immunoglobulins. High diversity of immune repertoire can be used as a prediction indicator for immune therapy. We can analyze the immune repertoire by TCR/BCR (T- and B-cell Receptor) sequencing.

« Show less
MHC Binding Prediction
Price on request

After identification of potential nonsynonymous mutations by WES and expression confirmation by RNA-Seq, HLA typing results can be used for predicting if such peptides could be presented by MHC and become epitopes that can be recognized by immune cells. Such information is useful for rational cancer vaccine design and precise immuno-therapy.

After identification of potential nonsynonymous mutations by WES and expression confirmation by RNA-Seq, HLA typing results can be used for predicting if such peptides could be presented by MHC and become epitopes that can be recognized by immune cells. Such information is useful for rational cancer vaccine design and precise immuno-therapy.

« Show less
Single Cell RNA-Seq
Price on request

To classify tumor infiltrating lymphocytes in the tumor micro-environment, gene expression signatures can be analyzed by single-cell RNA-seq from sorted immune cells extracted from tumor tissue. Tumor micro-environment and TIL (Tumor Infiltrating Lymphocyte) are important for understanding resistance to immuno-therapy.

To classify tumor infiltrating lymphocytes in the tumor micro-environment, gene expression signatures can be analyzed by single-cell RNA-seq from sorted immune cells extracted from tumor tissue. Tumor micro-environment and TIL (Tumor Infiltrating Lymphocyte) are important for understanding resistance to immuno-therapy.

« Show less
Biomarker Discovery
Price on request

Germline and somatic mutations are screened by WES. Gene expression signature can be assessed by transcriptome sequencing and epigenetic analysis. Our proprietary Aptamer based AptaNXTM platform can be used for biomarker (both macro-molecules and small molecules) screening with benefits of cost efficiency and short turn-around time.

Germline and somatic mutations are screened by WES. Gene expression signature can be assessed by transcriptome sequencing and epigenetic analysis. Our proprietary Aptamer based AptaNXTM platform can be used for biomarker (both macro-molecules and small molecules) screening with benefits of cost efficiency and short turn-around time.

« Show less
Neoantigen Identification
Price on request

Somatic mutations are screened by Whole Exome Sequencing (WES). Their expression is confirmed by transcriptome sequencing and epigenetic analysis. HLA typing is used to predict the presentation of such potential antigens by major histocompatibility complex (MHC).

Somatic mutations are screened by Whole Exome Sequencing (WES). Their expression is confirmed by transcriptome sequencing and epigenetic analysis. HLA typing is used to predict the presentation of such potential antigens by major histocompatibility complex (MHC).

« Show less
16S rRNA Sequencing
Starting at $100.00 per sample

Service description
The goal of 16S Ribosomal RNA Sequencing is to determine the type and relative abundance of bacterial and archaeal species in heterogeneous samples, such as soil, marine, or gut microbiome. Floracheck™ is a proprietary assay that improves upon current 16S metagenomics techniques with significant sensitivity... Show more »

Service description
The goal of 16S Ribosomal RNA Sequencing is to determine the type and relative abundance of bacterial and archaeal species in heterogeneous samples, such as soil, marine, or gut microbiome. Floracheck™ is a proprietary assay that improves upon current 16S metagenomics techniques with significant sensitivity and specificity. Side-by-side comparison with the most commonly used 16S metagenomics assays reveals that Floracheck™ has the ability to detect more bacterial and archaeal genera with a lower limit of detection for both environmental and mammalian species.

Advantages:
• Higher sensitivity
• Low bias
• Cost-effective
• Fast turnaround

Region coverage:
Floracheck™ Environmental (V3, V4, and V5 hypervariable regions)
Floracheck™ Mammalian(V3 and V4 hypervariable regions).
Floracheck Essential (V4 hypervariable region only)
Deliverables:
• Raw data as FASTQ files
• Chart detailing the type and relative abundance of bacterial and archaeal genera in each sample
Sequencing Depth:
Guaranteed 50MB data,deep coverage per request

TAT:
• 2 weeks

Sample Submission:
• Cell pellets
• High quality genomic DNA (a minimum of 100ng as quantified by Qubit 2.0)
• OD260/280 ratio is between 1.8 to 2.0
• OD260/230 ratio is between 1.5 to 2.0

Data security: biometrically restricted laboratory access,closed loop data behind firewall, and biometrically restricted data room

Promotion period:
Feburary 1, 2016 to May 24, 2016; minimum sample amount: 24

« Show less
Illumina MiSeq sequencing system
Human
Mouse
Bacteria
Immuno-oncology Assays
Price on request

Admera Health now provides comprehensive Immuno-Oncology solutions targeting key components in research discovery, clinical translation and therapeutics such as neoantigen identification, biomarker discovery, tumor micro environment, immune repertoire, ICI efficacy prediction and personalized cancer vaccine.

Services... Show more »

Admera Health now provides comprehensive Immuno-Oncology solutions targeting key components in research discovery, clinical translation and therapeutics such as neoantigen identification, biomarker discovery, tumor micro environment, immune repertoire, ICI efficacy prediction and personalized cancer vaccine.

Services includes:
1. Neoantigen Identification:
Somatic mutations are screened by Whole Exome Sequencing (WES). Their expression is confirmed by transcriptome sequencing and epigenetic analysis. HLA typing is used to predict the presentation of such potential antigens by major histocompatibility complex (MHC).
2. Biomarker discovery
Germline and somatic mutations are screened by WES. Gene expression signature can be assessed by transcriptome sequencing and epigenetic analysis. Our proprietary Aptamer based AptaNXTM platform can be used for biomarker (both macro-molecules and small molecules) screening with benefits of cost efficiency and short turn-around time.
3. MHC binding
After identification of potential nonsynonymous mutations by WES and expression confirmation by RNA-Seq, HLA typing results can be used for predicting if such peptides could be presented by MHC and become epitopes that can be recognized by immune cells. Such information is useful for rational cancer vaccine design and precise immuno-therapy.

  1. Single-cell RNA-Seq
    To classify tumor infiltrating lymphocytes in the tumor micro-environment, gene expression signatures can be analyzed by single-cell RNA-seq from sorted immune cells extracted from tumor tissue. Tumor micro-environment and TIL (Tumor Infiltrating Lymphocyte) are important for understanding resistance to immuno-therapy.

  2. Immune repertoire
    There are 6 key types of immune proteins including 4 types of T- cell receptors and 2 types of immunoglobulins. High diversity of immune repertoire can be used as a prediction indicator for immune therapy. We can analyze the immune repertoire by TCR/BCR (T- and B-cell Receptor) sequencing.

  3. Tumor Mutation Burden
    Tumor mutation burden is one of the indicators for Immune checkpoint inhibitor therapy efficacy. Patients with higher tumor mutation burden usually have better response to immuno-therapy such as PD-1 inhibitor. Admera Health offers WES and OncoGx DNA panel sequencing for tumor mutation burden analysis.

  4. MSI-H/dMMR
    A deficient mismatch repair (dMMR) system causes persistence of DNA mismatches in microsatellites. Tumors that have a dMMR system can develop MSI (microsatellite instability). Microsatellite instability high (MSI-H) phenotype can serve as a key indicator for ICI therapy efficacy. Admera Health offers MSI/dMMR and OncoGx DNA sequencing for MSI-H/dMMR analysis.

  5. Regulatable CAR-T
    Chimeric Antigen Receptor T-cell (CAR-T) therapy is one of the new immuno-therapies showing promising results. However, it has shortcomings such as off-targeting and toxicity in clinical trials. In order to overcome this, Admera Health has developed a regulatable CAR-T platform based on aptamer technology. The expression of CAR can be controlled by certain small molecules so that the side effects of CAR-T therapy can be controlled and minimized.

Combining the above technologies/platforms and our strong bioinformatic pipelines, Admera Health offersa comprehensive package of solutions to aid your immune-oncology studies. Please contact us for more service details.

« Show less
SMRT Sequencing
Single Molecule Real-Time Sequencing
Starting at $1,600.00 per smrtcell

PacBio Sequencer

The PacBio® RS II sequencing system allows scientists to rapidly and cost effectively generate finished genome assemblies, reveal and understand epigenomes, and characterize genomic variation. It achieves the industry’s longest read lengths and highest consensus accuracy.

The PacBio RS II is a Single... Show more »

PacBio Sequencer

The PacBio® RS II sequencing system allows scientists to rapidly and cost effectively generate finished genome assemblies, reveal and understand epigenomes, and characterize genomic variation. It achieves the industry’s longest read lengths and highest consensus accuracy.

The PacBio RS II is a Single Molecule, Real-Time (SMRT®) DNA Sequencing System that provides the highest consensus accuracy and longest read lengths of any available sequencing technology. SMRT Sequencing is ideal for de novo assembly,characterization of genetic variation, methylation analysis, microbiology studies, and more.

The instrument features high performance optics, automated liquid handling, and an environmental control center, all directed through an intuitive touchscreen interface. The computational brain responsible for primary data analysis, called the Blade Center, is also included. This allows for seamless integration of performance enhancements through chemistry and software advances.

« Show less
PacBio RS II
Customized Gene Panels
Price on request

Service description:
Targeted resequencing allows researchers to analyze a specific subset of the genome to discover and validate novel variants, examine specific genes in pathways, or as a follow-up to GWAS data. Based on prior knowledge of the region of interest, custom targeted sequencing aims to only sequence the specified... Show more »

Service description:
Targeted resequencing allows researchers to analyze a specific subset of the genome to discover and validate novel variants, examine specific genes in pathways, or as a follow-up to GWAS data. Based on prior knowledge of the region of interest, custom targeted sequencing aims to only sequence the specified subset of the genome to enable maximum utilization of the NGS platform by giving the deepest genetic analysis compared to WGS and Exome-Seq. Depending on the genes for your target, we can design up to 40 million base pairs and perform the gene sequencing for your specific project. Each project is given special attention and designed exclusively.

• Advantages:
a) High coverage depth and uniformity
b) Short TAT
c) Accurate results

• Service grade:
a) Research Use Only (RUO) in a CLIA environment

• Genes/regions covered
a) In flexibility to target 1-1000 genes

• Deliverables
a) FASTQ, BAM and VCF files
b) Variant annotation

• Sequencing depth*
a) Mean depth of coverage: ≥ 250x
b) 90% of exons covered at ≥ 50x depth
*Higher depth of coverage available for additional charges, please inquire for details

• TAT
a) 3 weeks

• Sample requirements
Types of samples accepted:
a) FFPE slides
b) Saliva (please request sample collection supplies)
c) 5 ml Blood in a EDTA-coated tube
d) High quality genomic human DNA: a minimum of 2.0 microgram as quantified by Qubit 2.0

Purity of genomic human DNA samples:
a) OD260/280 ratio is between 1.8 to 2.0
b) OD260/230 ratio is between 1.5 to 2.0

• Sequencing platforms:
a) Illumina NextSeq paired-end 2x150 bp reads
b) Illumina HiSeq paired-end 2x150 bp reads

• Library preparation options:
a) xGen® target capture products
b) TruSeq Custom Amplicon Low Input Library Prep Kit
c) Powered by the SmartChip™ technology, WaferGene technology based singleplex PCR

• Data security
a) Biometrically restricted laboratory access and closed loop data behind firewall and biometrically restricted data room

• Promotion period
a) February 1, 2016 to May 24, 2016, minimum sample amount: 8

« Show less
Illumina MiSeq sequencing system
Illumina NextSeq 500 sequencing system
Human
Tophat
Cuffdiff
GATK
xGen Lockdown Panels
Clinical Biomarkers
Price on request

Your Complete Clinical Biomarker Solution Partner
Admera Health discovers, develops, and commercializes non-invasive clinical biomarkers and diagnostic tests. We are a trusted partner to biopharmaceutical companies and biomedical institutions, enabling their efforts to bring the most effective personalized therapies to global... Show more »

Your Complete Clinical Biomarker Solution Partner
Admera Health discovers, develops, and commercializes non-invasive clinical biomarkers and diagnostic tests. We are a trusted partner to biopharmaceutical companies and biomedical institutions, enabling their efforts to bring the most effective personalized therapies to global markets.

Our Ability to Deliver
Admera Health provides effective clinical biomarker solutions to meet your needs throughout the entire discovery, development, approval, and commercialization process. Our client can depend on us to deliver the following high quality services:
• Experiment design
• Feasibility studies
• Novel biomarker discovery
• Clinical validation
• Companion diagnostic development
• Regulatory approval
• CLIA-certified, CAP-accredited laboratory services
• Commercialization of clinical tests to global markets
• Project management and customer service
• Reimbursement

Our Technology Platforms and Advantages
We have set up an array of technology platforms to discover and develop different types of clinical biomarkers, including but not limited to DNA mutation, RNA (mRNA, smRNA, miRNA), protein and metabolite biomarkers.

In particular, we have proprietary platforms that are suitable for developing non-invasive clinical biomarkers:

• BEST: this blocker-based enrichment technology preferentially amplifies circulating tumor DNA (ctDNA) in blood and reliably identifies genetic alterations. We offer this technology on both qPCR and NGS platform. An added benefit of using NGS is the ability to accurately quantify ctDNA abundance, thus indicating tumor burden.
• CiRiSeq: this technology incorporates an innovative non-blocker non-probe based method to enrich genes and regions of interest. Its near error-free deep sequencing technology is ideal for novel rare mutation discovery.
• UltraD: this aptamer-based technology uses single-stranded nucleic acid to bind to targets including proteins and small molecules in a similar fashion to antibodies. Compared to traditional antibodies, UltraD has advantages such as easy chemical synthesis and modification, short development time, reduced cost, batch consistency, stability, and long shelf-life. Hence, it’s more suitable for the development of novel clinical applications.
Key Features & Benefits:
• Complete solutions include biomarker discovery and validation, as well as development and processing of clinically relevant assays and companion diagnostics.
• Expertise with and availability of multiple technology platforms, including liquid biopsy, aptamer, next generation sequencing, and qPCR.
• State-of-the-art CLIA-certified, and CAP-accredited laboratory.
• Pre-designed solutions and CLIA-certified tests for oncology, cardiovascular and pharmacogenomics diagnostics.
• Extensive experience in obtaining regulatory approval and commercialization of Lab Developed Tests (LDTs) globally, especially in US and China.

Accreditations:
Centers for Medicare & Medicaid Services (CMS)
Clinical Laboratory Improvement Amendments (CLIA)
College of American Pathologists (CAP) Accredited

« Show less
Illumina MiSeq sequencing system
Illumina NextSeq 500 sequencing system
fluorescence reader
Automated liquid handler
Aptamer Selection Service
Price on request

Aptamers are single-stranded DNA or RNA (ssDNA or ssRNA) molecules that can bind to pre-selected targets including proteins and peptides with high affinity and specificity. Similar to antibodies, aptamers interact with their targets by recognizing a specific three-dimensional structure and are thus termed “chemical antibodies.” In... Show more »

Aptamers are single-stranded DNA or RNA (ssDNA or ssRNA) molecules that can bind to pre-selected targets including proteins and peptides with high affinity and specificity. Similar to antibodies, aptamers interact with their targets by recognizing a specific three-dimensional structure and are thus termed “chemical antibodies.” In contrast to protein antibodies, aptamers offer unique chemical and biological characteristics based on their oligonucleotide properties, with advantages of easy chemical synthesis and modification, short development time, reduced cost, batch consistency, stability, and long shelf-life. Hence, they are more suitable for the development of novel clinical applications. Aptamer technology has been widely investigated in various biomedical fields for biomarker discovery, in vitro diagnosis, in vivo imaging, and targeted therapy.
• Service Description:
We offer the following custom aptamer services:
1) Aptamer design and characterization against known targets
2) Novel biomarker discovery
3) Aptamer-based companion diagnostic development
4) Aptamer-based therapeutic target validation and drug development

• Advantages:
a) More than 10 years’ experience and expertise in aptamer technology
b) Strong track record in developing clinical tests
c) Proprietary technology platforms
d) Reduced cost and shorter TAT
e) CLIA environment

• Deliverables:
a) Desired aptamer products with characterized sequence and affinity.
b) Novel biomarkers (proteins, peptides, small molecules)
c) Aptamer-based companion diagnostics
d) Aptamer-based drug leads

• Turn Around Time (TAT)
a) 4-12 weeks for aptamer design and characterization.
b) For biomarker discovery, aptamer-based companion diagnostics and drug leads, it depends on the complexity of the projects.

• Sample Requirements
a) For aptamer development against known targets, customers need to provide the targets (proteins, peptides, small molecules).
b) For other services such as biomarker discovery, aptamer-based diagnostic and therapeutic development, customers need to provide specimens (plasma / body fluids / cells) and relevant information.

« Show less
Comprehensive Cancer Gene Panel
Price on request

• Service description:
Three types of cancer panels are offered through our CLIA certified, CAP accredited laboratory. These services provide comprehensive genomic analysis for cancer research, biomarker discovery and/or companion diagnostics. Designed and developed with the most recent clinical data and validated on human... Show more »

• Service description:
Three types of cancer panels are offered through our CLIA certified, CAP accredited laboratory. These services provide comprehensive genomic analysis for cancer research, biomarker discovery and/or companion diagnostics. Designed and developed with the most recent clinical data and validated on human samples, OncoGxOne™ and OncoGxOne™ Plus analyze 64 and 333 cancer related genes, respectively, while OncoGxCustom™ analyzes any combination of genes chosen by customers. All panels detect four genomic variations including point mutation, small insertion/deletion, copy number variation and gene fusion.

• Advantages:
a) Low cost
b) High coverage depth and uniformity
c) Short TAT

• Service grade:
a) OncoGxOne™ (RUO or CLIA)
b) OncoGxOne™ Plus (RUO)
c) OncoGxCustom™ (RUO)

• Genes covered:
a) OncoGxOne™: 64 genes. Please refer to the Appendix 1 for the complete gene list
b) OncoGxOne™ Plus: 333 genes. Please refer to the Appendix 2 for the complete gene list
c) OncoGxCustom™: any combination of genes chosen by customers
d) Ion AmpliSeq™ Cancer Hotspot Panel v2
e) Ion AmpliSeq™ RNA Cancer Panel
f) TruSeq Amplicon - Cancer Panel
g) TruSight Cancer
h) TruSight Tumor
i) TruSight Cancer
j) TruSight Cancer

• Deliverables:
a) FASTQ, BAM and VCF files
b) Variant annotation
c) Medically actionable report available for additional charges, please inquire for details

• Sequencing depth:
a) Mean depth of coverage: ≥ 250x
b) 90% of exons covered at ≥ 20x depth
c) Higher depth of coverage available for additional charges, please inquire for details.

• TAT:
a) 14 days for OncoGxOne™ and OncoGxOne™ Plus
b) Please inquire for OncoGxCustom™

• Sample Requirements
a) Fresh frozen tissue: No less than 100mg frozen tissue should be sent in a sealed tube overnight on dry ice. Tissue should be kept frozen throughout the whole transport.
b) FFPE: The optimal tissue contains ≥ 1 mm^3 tissue (≥ 25 mm^2 surface area x 40 µm depth) on 8 to 10 unstained slides. The tissue Nucleated cellularity should be ≥ 80% or ≥ 30,000 cells. The optimal tumor content is ≥ 20%. Note: for liver specimens, the optimal tumor content is ≥ 30%.
c) Blood: 5 mL of whole blood can used as normal control tissue sample. Please send it in Lavender top tubes (containing EDTA).

• Sequencing platforms:
a) Illumina Miseq paired-end 2x150 bp
b) Illumina Nextserq paired-end 2x150 bp

• Library preparation options:
a) Agilent Technologies SureSelect Target Enrichment system
b) IDT xGen® Lockdown® Probes

• Data security: biometrically restricted laboratory access and closed loop data behind firewall and data room also biometrically restricted

• Appendix 1:
OncoGxOne™ gene list
ABL1 BRAF CTNNB1 ESR1 HRAS MET PDGFRA RUNX1
AKT1 BRCA1 CYP2C8 ETV6 IDH1 MLL PDGFRB SMO
ALK BRCA2 CYP2D6 FGFR1 IDH2 MPL PIK3CA TP53
ATM CCND1 DDR2 FGFR2 JAK1 MTHFR PTCH1 TPMT
AURKA CCNE1 DNMT3A FGFR3 JAK2 MYC PTEN TSC1
BCL2 CDK4 DPYD FLT3 KIT NF1 RARA TYMS
BCL6 CEBPA EGFR GNA11 KRAS NPM1 RET UGT1A1
BCR CRLF2 ERBB2 GNAQ MAP2K1 NRAS ROS1 XRCC1

• Appendix 2:
OncoGxOne™ Plus gene list
ABL1 APCDD1 ATM BACH1 BCR CARD11 CD79A CDKN1B
ACVR1B AR ATR BAP1 BLM CASP8 CD79B CDKN2A
AKT1 ARAF ATRX BARD1 BRAF CBFB CDC73 CDKN2B
AKT2 ARFRP1 AURKA BCL2 BRCA1 CBL CDH1 CDKN2C
AKT3 ARID1A AURKB BCL2L2 BRCA2 CCND1 CDK12 CEBPA
ALK ARID1B AXIN1 BCL6 BRIP1 CCND2 CDK4 CHEK1
ALOX12B ARID2 AXL BCOR BTG1 CCND3 CDK6 CHEK2
APC ASXL1 B2M BCORL1 BTK CCNE1 CDK8 CHUK

CIC CTNNB1 DAXX ELF3 ERBB3 EWSR1 FANCF FGF14
CRBN CUL4A DDR2 EMSY ERBB4 EZH2 FANCG FGF19
CREBBP CUL4B DIS3 EP300 ERG FAM123B FANCI FGF23
CRKL CUX1 DNMT1 EPHA3 ESR1 FAM46C FANCL FGF3
CRLF2 CYLD DNMT3A EPHA5 ETV1 FANCA FANCM FGF4
CSF1R CYP17A1 DOT1L EPHB1 ETV4 FANCC FAT3 FGF6
CTCF CYP2C8 DPYD EPOR ETV5 FANCD2 FBXW7 FGF7
CTNNA1 CYP2D6 EGFR ERBB2 ETV6 FANCE FGF10 FGFR1

FGFR2 GATA1 GPR124 HLA-C IGF2R JAK2 KEAP1 MAP2K1
FGFR3 GATA2 GRIN2A HNF1A IKBKE JAK3 KIT MAP2K2
FGFR4 GATA3 GSK3B HRAS IKZF1 JUN KLF4 MAP2K4
FLT1 GID4 (C17orf39) H3F3A IDH1 IL7R KAT6A KLHL6 MAP3K1
FLT3 GNA11 HGF IDH2 INHBA KDM5A KRAS MAP3K13
FLT4 GNA13 HIST1H3B IGF1 IRF4 KDM5C LMO1 MAPK1
FOXL2 GNAQ HLA-A IGF1R IRS2 KDM6A LRP1B MCL1
FUBP1 GNAS HLA-B IGF2 JAK1 KDR MAML1 MDM2

MDM4 MLL2 MUTYH NF1 NOTCH4 PAK3 PBRM1 PIK3CG
MED12 MLL3 MYC NF2 NPM1 PAK7 PDGFRA PIK3R1
MEF2B MPL MYCL1 NFE2L2 NRAS PALB2 PDGFRB PIK3R2
MEN1 MRE11A MYCN NFKBIA NSD1 PARP1 PDK1 PMS2
MET MSH2 MYD88 NKX2-1 NTRK1 PARP2 PHF6 PNRC1
MITF MSH6 NBN NOTCH1 NTRK2 PARP3 PIK3C2G PPP2R1A
MLH1 MTHFR NCOA3 NOTCH2 NTRK3 PARP4 PIK3C3 PRDM1
MLL MTOR NCOR1 NOTCH3 NUP93 PAX5 PIK3CA PRKAR1A

PRKDC RAD51C RET SETBP1 SMARCA4 SPEN STK11 TNFAIP3
PRSS8 RAD51D RICTOR SETD2 SMARCB1 SPOP SUFU TNFRSF14
PTCH1 RAD52 RNF43 SF3B1 SMARCD1 SRC SYK TOP1
PTEN RAD54L ROS1 SH2B3 SMO SRSF2 TBX3 TP53
PTPN11 RAF1 RPA1 SKP2 SOCS1 STAG2 TET2 TPMT
RAD50 RARA RPTOR SMAD2 SOX10 STAT1 TGFBR2 TRAF7
RAD51 RB1 RUNX1 SMAD3 SOX2 STAT3 TIPARP TRRAP
RAD51B REL RUNX1T1 SMAD4 SOX9 STAT4 TMPRSS2 TSC1

TSC2 XPO1
TSHR XRCC1
TYMS XRCC3
U2AF1 ZNF217
UGT1A1 ZNF703
VHL
WISP3
WT1

« Show less
Illumina MiSeq sequencing system
Illumina NextSeq 500 sequencing system
Human
Illumina HiSeq 4000
xGen Lockdown Panels
Agilent SureSelect
Breast Cancer Gene Panel
Starting at $198.00 per sample

iBRCA™ is a breast cancer risk panel, which detects genetic variations in all exons of BRCA1 and BRCA2. It is currently offered as a Research Use Only (RUO) service. Guided by ClinVar of National Center for Biotechnology Information (NCBI), iBRCA™ offers high accuracy, quick 10-day TAT and affordable cost. Tests are processed in... Show more »

iBRCA™ is a breast cancer risk panel, which detects genetic variations in all exons of BRCA1 and BRCA2. It is currently offered as a Research Use Only (RUO) service. Guided by ClinVar of National Center for Biotechnology Information (NCBI), iBRCA™ offers high accuracy, quick 10-day TAT and affordable cost. Tests are processed in CLIA

• Advantages:
a) Low cost
b) High coverage depth and uniformity
c) Short TAT

• Service grade:
RUO (research use only)

• Genes covered:
All exons of BRCA1 and BRCA2 (including UTR and CDS) and splicing regions (flanking intron regions 10bp upstream and downstream of exons)

• Deliveries:
a) FASTQ, BAM and VCF files
b) Variant annotation
c) Technical report

• Sequencing depth:
a) Mean depth of coverage: 300X
b) 90% of exons covered at ≥ 100x depth or 99% of exons covered at ≥ 20x depth

• TAT:
10 days

• Sample Requirements
a) High quality gDNA in water or low TE (10mM Tris-HCl, pH8.0, 0.1 mM EDTA) with amount ≥ 1ug and concentration ≥5ng/ul, quantified by Qubit 2.0.
OD260/280 ratio is between 1.8 to 2.0
OD260/230 ratio is between 1.5 to 2.0
b) Buccal Swabs: Requires two swabs per customer. (please request sample collection supplies and follow swab instructions)
c) Saliva: Please request sample collection supplies and follow the instructions.

• Sequencing platforms:
Illumina Miseq paired-end 2x150 bp

• Library preparation options:
Powered by the SmartChip™ technology, take advantage of massively-parallel, singleplex PCR to simultaneously enrich a large number of target regions and incorporate sequencing adapters and barcodes to produce sequencing-ready libraries in one simple step.

• Data security:
Biometrically restricted laboratory access and closed loop data behind firewall and data room also biometrically restricted

« Show less
Illumina MiSeq sequencing system
Next Seq 500
Human
Clinical Chemistry
Price on request
Request a quote for more information about this service.
Exome Sequencing Services
Price on request
Request a quote for more information about this service.
RNA Services
Price on request
Request a quote for more information about this service.
Biomarkers
Price on request
Request a quote for more information about this service.
Clinical Immunology Tests
Price on request
Request a quote for more information about this service.
Genetic Marker Screening Services
Price on request
Request a quote for more information about this service.
Clinical Research
Price on request
Request a quote for more information about this service.
Clinical Laboratory Services
Price on request
Request a quote for more information about this service.
Aptamers
Price on request
Request a quote for more information about this service.
Genotyping Services
Price on request
Request a quote for more information about this service.
Gene Panel Testing
Price on request
Request a quote for more information about this service.
Nucleic Acid Services
Price on request
Request a quote for more information about this service.
Protein Services
Price on request
Request a quote for more information about this service.
DNA Synthesis and Probe Development
Price on request
Request a quote for more information about this service.
Antibody Services
Price on request
Request a quote for more information about this service.
Targeted Gene Sequencing
Price on request
Request a quote for more information about this service.
Biochemistry & Molecular Biology
Price on request
Request a quote for more information about this service.
Next Generation Sequencing (NGS)
Price on request
Request a quote for more information about this service.
Biology
Price on request
Request a quote for more information about this service.
Antibody/Antigen Detection Based Testing
Price on request
Request a quote for more information about this service.
Immunoassays
Price on request
Request a quote for more information about this service.
DNA Library Construction Services
Price on request
Request a quote for more information about this service.
Bioanalysis
Price on request
Request a quote for more information about this service.
PCR
Price on request
Request a quote for more information about this service.
DNA Sequencing
Price on request
Request a quote for more information about this service.
DNA Services
Price on request
Request a quote for more information about this service.
Clinical Molecular Diagnostics
Price on request
Request a quote for more information about this service.
DNA Extraction and Purification
Price on request
Request a quote for more information about this service.
RNA Extraction and Purification
Price on request
Request a quote for more information about this service.
2018-09-24 15:57:27 -0700

Net Promoter Score of 10 received for RNA Sequencing.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2018-09-17 07:41:28 -0700

Net Promoter Score of 10 received for Metagenomics.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2018-06-20 10:12:17 -0700

Net Promoter Score of 10 received for Next Generation Sequencing (NGS).

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2018-06-08 12:08:22 -0700

Net Promoter Score of 9 received for Next Generation Sequencing (NGS).

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2018-05-10 14:25:35 -0700

Net Promoter Score of 10 received for Illumina MiSeq Sequencing.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2018-05-09 05:12:23 -0700

Net Promoter Score of 9 received for Comprehensive Cancer Gene Panel.

Additional Ratings: satisfaction with deliverable: 6, satisfaction with timeliness: 6.
2018-04-16 06:49:05 -0700

Net Promoter Score of 9 received for Whole Exome Sequencing (WES).

Additional Ratings: satisfaction with deliverable: 9, satisfaction with timeliness: 9.
2018-03-29 13:59:43 -0700

Net Promoter Score of 9 received for 16S rRNA Sequencing.

Additional Ratings: satisfaction with deliverable: 9, satisfaction with timeliness: 9.
2018-03-14 05:20:43 -0700

Net Promoter Score of 10 received for qPCR.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2018-02-23 05:14:19 -0800

Net Promoter Score of 10 received for RNA Sequencing.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2018-02-22 10:01:00 -0800

Net Promoter Score of 7 received for RNA Sequencing.

Additional Ratings: satisfaction with deliverable: 6, satisfaction with timeliness: 9.
2018-02-22 09:26:10 -0800

Net Promoter Score of 9 received for qPCR.

Additional Ratings: satisfaction with deliverable: 9, satisfaction with timeliness: 9.
February 22, 2018

Positive review received for qPCR:

"On time, analysis well explained"

2018-02-14 04:21:53 -0800

Net Promoter Score of 10 received for RNA Sequencing.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2018-01-31 07:49:09 -0800

Net Promoter Score of 10 received for Whole Genome Sequencing.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2018-01-30 15:24:38 -0800

Net Promoter Score of 10 received for RNA Sequencing.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2017-12-11 17:04:49 -0800

Net Promoter Score of 7 received for RNA Sequencing.

Additional Ratings: satisfaction with deliverable: 8, satisfaction with timeliness: 6.
December 7, 2017

Positive review received for Whole Genome Sequencing:

"It was a pleasure to work with Admera Health. Fast service, quality data and transparent communications."

2017-12-04 15:00:37 -0800

Net Promoter Score of 10 received for Whole Genome Sequencing.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2017-11-28 08:32:16 -0800

Net Promoter Score of 10 received for Comprehensive Cancer Gene Panel.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 9.
2017-10-10 08:01:24 -0700

Net Promoter Score of 9 received for RNA Sequencing.

Additional Ratings: satisfaction with deliverable: 9, satisfaction with timeliness: 9.
2017-09-17 22:35:38 -0700

Net Promoter Score of 10 received for RNA Sequencing.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2017-09-12 13:12:32 -0700

Net Promoter Score of 10 received for Amplicon Sequencing.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2017-07-05 15:39:52 -0700

Net Promoter Score of 10 received for Metagenomics.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2017-07-05 15:20:58 -0700

Net Promoter Score of 10 received for RNA Sequencing.

Additional Ratings: satisfaction with deliverable: 8, satisfaction with timeliness: 9.
May 19, 2017

Positive review received for RNA Sequencing:

"They performed a very good job with my RNAseq project. They were always available to answer questions and clarify issues."

2017-02-21 12:09:00 -0800

Net Promoter Score of 10 received for Whole Exome Sequencing (WES).

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
2017-02-21 12:07:23 -0800

Net Promoter Score of 10 received.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
February 17, 2017

Positive review received for 16S rRNA Sequencing:

"Great service! Everything was in time and the analysis was finished even earlier than initially projected. The price is very reasonable."

January 3, 2017

Positive review received for Whole Genome Sequencing:

"Reasonable pricing and quick turnaround. Will recommmend and reuse."

December 14, 2016

Positive review received for Whole Exome Sequencing (WES):

"Quick and efficient communication. Flexible on quotes. Provided everything needed from saliva tubes, shipping labels, raw data, and important metadata for downstream analyses."

2016-09-28 19:20:22 -0700

Net Promoter Score of 10 received for 16S rRNA Sequencing.

Additional Ratings: satisfaction with deliverable: 10, satisfaction with timeliness: 10.
August 18, 2016

Positive review received for 16S rRNA Sequencing:

"Very responsive to email great customer service and a very fast turn around time. I highly recommend and will use them again!"

July 28, 2016

Positive review received for Biomarker Analysis:

"Admera Health LLC is very Professional and helpful. They are very responsive to questions and are very helpful. i would highly recommend the company."

July 19, 2016

Positive review received for 16S rRNA Sequencing:

"Highly professional, responsive and dilligent."

June 29, 2016

Positive review received for Breast Cancer Gene Panel:

"The team working at Admera possesses a unique combination of extreme professionalism and commitment to deliver the highest quality services. This was my first order with this company, and I definitely will consider them in future projects. Several key characteristics that made me as satisfied with their services include, but not limited to: 1. Speed of results generation 2. Thorough quality check of samples and results 4. Comprehensive reporting and delivery of raw data 3. Extreme helpfulness and fast communication Finally, I would like to thank all members of Admera with whom I communicated during this period for a wonderful job and promising results."

2016-06-20 17:29:58 -0700

Net Promoter Score of 10 received.

May 8, 2016

Positive review received for Whole Exome Sequencing (WES):

"Admera health was very professional with a quad whole exome study that we were conducting on their Nextseq 500 platform. Samples were prepared well and we received results within a week of getting all our samples to them. We also ran two identical samples to determine the consistency of their platform and library preparation and we only had about 5 new SNP in each sample which is consistent with what we expected. Overall I would highly recommend this service and will be using them again for future WES needs."

March 28, 2016

Positive review received for 16S rRNA Sequencing:

"The company did 16S rRNA gene profiling by sequencing V3 and V4 regions. DNA purification and sequencing were done within two weeks. The coverage between samples were quite even with more than a million reads per sample. Sequence quality was excellent. The company was proactive in communication with me as well."

Be the first to endorse Admera Health LLC

Endorse this lab